Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma

Human Pathology

Volumn 39, Issue 12, 2008, Pages 1777-1783

  Korita, Pavel V ^a   Wakai, Toshifumi ^a   Shirai, Yoshio ^a   Matsuda, Yasunobu ^a   Sakata, Jun ^a   Cui, Xing ^b   Ajioka, Yoichi ^a   Hatakeyama, Katsuyoshi ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Cell adhesion molecules; Hepatocellular carcinoma; Osteopontin; Prognosis; Vascular invasion

Indexed keywords

BETA CATENIN; CELL ADHESION MOLECULE; OSTEOPONTIN; UVOMORULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER SIZE; CANCER SURVIVAL; CELL INVASION; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPANESE; LIVER CELL CARCINOMA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RISK FACTOR;

ADOLESCENT; ADULT; AGED; BETA CATENIN; CADHERINS; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HEPATECTOMY; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OSTEOPONTIN; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 55949125559     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.05.006     Document Type: Article

References (35)

1. Senger D.R., Wirth D.F., and Hynes R.O. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16 (1979) 885-893
2. Takafuji V., Forgues M., Unsworth E., Goldsmith P., and Wang X.W. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26 (2007) 6361-6371
3. Lin Y.H., and Yang-Yen H.F. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 276 (2001) 46024-46030
4. Ye Q.H., Qin L.X., Forgues M., et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9 (2003) 416-423
5. Greene F.L., Page D.L., Fleming I.D., et al. AJCC Cancer Staging Manual. 6th ed. (2002), Springer-Verlag, New York 131-138
6. Pignatelli M., and Vessey C.J. Adhesion molecules: novel molecular tools in tumor pathology. Hum Pathol 25 (1994) 849-856
7. Nair K.S., Naidoo R., and Chetty R. Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol 58 (2005) 343-351
8. Cruz P.V., Wakai T., Shirai Y., Yokoyama N., and Hatakeyama K. Loss of carcinoembryonic antigen-related cell adhesion molecule 1 expression is an adverse prognostic factor in hepatocellular carcinoma. Cancer 104 (2005) 354-360
9. Kozyraki R., Scoazec J.Y., Flejou J.F., et al. Expression of cadherins and alpha-catenin in primary epithelial tumors of the liver. Gastroenterology 110 (1996) 1137-1149
10. Wei Y., Van Nhieu J.T., Prigent S., Srivatanakul P., Tiollais P., and Buendia M.A. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology 36 (2002) 692-701
11. Pan H.W., Ou Y.H., Peng S.Y., et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98 (2003) 119-127
12. Gotoh M., Sakamoto M., Kanetaka K., Chuuma M., and Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 52 (2002) 19-24
13. Asayama Y., Taguchi Ki K., et al. The mode of tumour progression in combined hepatocellular carcinoma and cholangiocarcinoma: an immunohistochemical analysis of E-cadherin, alpha-catenin and beta-catenin. Liver 22 (2002) 43-50
14. Nishi H., Taguchi K., Asayama Y., et al. Sarcomatous hepatocellular carcinoma: a special reference to ordinary hepatocellular carcinoma. J Gastroenterol Hepatol 18 (2003) 415-423
15. Wakai T., Shirai Y., Sakata J., et al. Anatomic resection independently improves long-term survival in patients with T1-T2 hepatocellular carcinoma. Ann Surg Oncol 14 (2007) 1356-1365
16. Taylor M., Forster J., Langer B., Taylor B.R., Greig P.D., and Mahut C. A study of prognostic factors for hepatic resection for colorectal metastases. Am J Surg 173 (1997) 467-471
17. Edmondson H.A., and Steiner P.E. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7 (1954) 426-503
18. Ihara A., Koizumi H., Hashizume R., and Uchikoshi T. Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology 23 (1996) 1441-1447
19. Wong C.M., Fan S.T., and Ng I.O. Beta-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 92 (2001) 136-145
20. Endo K., Ueda T., Ueyama J., Ohta T., and Terada T. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum Pathol 31 (2000) 558-565
21. Iso Y., Sawada T., Okada T., and Kubota K. Loss of E-cadherin mRNA and gain of osteopontin mRNA are useful markers for detecting early recurrence of HCV-related hepatocellular carcinoma. J Surg Oncol 92 (2005) 304-311
22. McGee J.O., Isaacson P.G., and Wright N.A. Cellular organization and cellular interrelationships. In: Dick H.M., and Slack M.P. (Eds). Oxford textbook of pathology Vol. 1 (1992), Oxford University Press, Oxford 3-33
23. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251 (1991) 1451-1455
24. Frixen U.H., Behrens J., Sachs M., et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113 (1991) 173-185
25. Ue T., Yokozaki H., Kitadai Y., et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 79 (1998) 127-132
26. Adachi E., Maeda T., Kajiyama K., et al. Factors correlated with portal venous invasion by hepatocellular carcinoma: univariate and multivariate analyses of 232 resected cases without preoperative treatments. Cancer 77 (1996) 2022-2031
27. Jonas S., Bechstein W.O., Steinmuller T., et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33 (2001) 1080-1086
28. Pawlik T.M., Delman K.A., Vauthey J.N., et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 11 (2005) 1086-1092
29. Yuan R.H., Jeng Y.M., Chen H.L., et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 209 (2006) 549-558
30. Xie H., Song J., Du R., et al. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis 39 (2007) 167-172
31. Shevde L.A., Samant R.S., Paik J.C., et al. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 23 (2006) 123-133
32. Hotte S.J., Winquist E.W., Stitt L., Wilson S.M., and Chambers A.F. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95 (2002) 506-512
33. Wai P.Y., Mi Z., Gao C., Guo H., Marroquin C., and Kuo P.C. Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells. J Biol Chem 281 (2006) 18973-18982
34. Chambers A.F., Wilson S.M., Kerkvliet N., O'Malley F.P., Harris J.F., and Casson A.G. Osteopontin expression in lung cancer. Lung Cancer 15 (1996) 311-323
35. Zhang H., Ye Q.H., Ren N., et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 132 (2006) 709-717